Clinical Trial Update: Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of lenalidomide and obinutuzumab in patients with recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2022-09-28